                                                                                                                                   II




                                  113TH CONGRESS
                                     1ST SESSION                            S. 133
                                  To protect all patients by prohibiting the use of data obtained from compara-
                                      tive effectiveness research to deny or delay coverage of items or services
                                      under Federal health care programs and to ensure that comparative
                                      effectiveness research accounts for advancements in personalized medicine
                                      and differences in patient treatment response.




                                              IN THE SENATE OF THE UNITED STATES
                                                JANUARY 24 (legislative day, JANUARY 3), 2013
                                  Mr. ROBERTS (for himself, Mr. COBURN, Mr. BARRASSO, Mr. PORTMAN, Mr.
                                      CRAPO, Mr. INHOFE, and Mr. VITTER) introduced the following bill;
                                      which was read twice and referred to the Committee on Health, Edu-
                                      cation, Labor, and Pensions




                                                                            A BILL
                                  To protect all patients by prohibiting the use of data ob-
                                     tained from comparative effectiveness research to deny
                                     or delay coverage of items or services under Federal
                                     health care programs and to ensure that comparative
                                     effectiveness research accounts for advancements in per-
                                     sonalized medicine and differences in patient treatment
                                     response.
                                    1              Be it enacted by the Senate and House of Representa-
                                    2 tives of the United States of America in Congress assembled,





                                    1     SECTION 1. SHORT TITLE.                            2
                                    2              This Act may be cited as the ‘‘Preserving Access to
                                    3 Targeted, Individualized, and Effective New Treatments
                                    4 and Services (PATIENTS) Act of 2013’’ or the ‘‘PA-
                                    5 TIENTS Act of 2013’’.
                                    6     SEC. 2. PROHIBITION ON CERTAIN USES OF DATA OB-
                                    7                             TAINED            FROM          COMPARATIVE                      EFFECTIVE-
                                    8                             NESS RESEARCH; ACCOUNTING FOR PERSON-
                                    9                             ALIZED MEDICINE AND DIFFERENCES IN PA-
                                  10                              TIENT TREATMENT RESPONSE.

                                  11               (a) IN GENERAL.—Notwithstanding any other provi-
                                  12 sion of law, the Secretary of Health and Human Serv-
                                  13 ices—
                                  14                         (1) shall not use data obtained from the con-
                                  15               duct of comparative effectiveness research, including
                                  16               such research that is conducted or supported using
                                  17               funds appropriated under the American Recovery
                                  18               and Reinvestment Act of 2009 (Public Law 111–5)
                                  19               or authorized or appropriated under the Patient
                                  20               Protection and Affordable Care Act (Public Law
                                  21               111–148), to deny or delay coverage of an item or
                                  22               service under a Federal health care program (as de-
                                  23               fined in section 1128B(f) of the Social Security Act
                                  24               (42 U.S.C. 1320a–7b(f))); and





                                  25                         (2) shall ensure that comparative effectiveness
                                  26               research conducted or supported by the Federal
                                              •S 133 IS

                                                                                             3
                                    1              Government accounts for factors contributing to dif-
                                    2              ferences in the treatment response and treatment
                                    3              preferences of patients, including patient-reported
                                    4              outcomes, genomics and personalized medicine, the
                                    5              unique needs of health disparity populations, and in-
                                    6              direct patient benefits.
                                    7              (b) RULE            OF    CONSTRUCTION.—Nothing in this sec-
                                    8 tion shall be construed as affecting the authority of the
                                    9 Commissioner of Food and Drugs under the Federal
                                  10 Food, Drug, and Cosmetic Act or the Public Health Serv-
                                  11 ice Act.
                                              •S 133 IS                                    Æ
